Targeting Cancer Pathways: The Tumor Microenvironment скачать в хорошем качестве

Targeting Cancer Pathways: The Tumor Microenvironment

Rakesh K. Jain, PhD (Harvard Medical School/MGH), and Padmanee Sharma, MD, PhD (MD Anderson Cancer Center) ⬇️ Expand “Show More” to view abstract and table of contents Dive deeper into the tumor microenvironment: https://cst-science.com/g5zkn1 This webinar explores how the tumor microenvironment promotes oncogenic progression, while protecting the tumor from therapeutic intervention. By better understanding the tumor microenvironment we can develop strategies and treatment options to neutralize its oncogenic influence and more effectively attack the tumor itself. Topics covered include: • The importance of understanding the tumor microenvironment and how it interacts with normal cells; • What can be learned from the tumor microenvironment that might allow better, more effective therapeutics to be developed; • How the abnormal microenvironment impacts anti-cancer drugs and how manipulating it with antiangiogenics can improve therapeutic outcomes. Table of Contents 0:00 Welcome and overview 2:34 Rakesh Jain speaker profile 3:20 Reengineering the TME to enhance cancer treatment: bench to bedside to biomarkers 5:16 In vivo imaging of tumors 5:51 Blood vessels in glioblastoma 8:00 Impaired blood perfusion contributes to hypoxia and low pH 9:04 Interstitial fluid pressure in human tumors 9:37 Hypoxia and low pH fuel cancer hallmarks 11:08 Understanding impaired blood flow in tumors 12:45 Vascular normalization hypothesis 14:05 Cediranib treatment can increase tumor blood perfusion 14:54 Patients with increased perfusion survived ~9 months longer 15:47 Low dose anti-VEGFR2 treatment improves perfusion 19:10 Calculating tumor solid stress 20:23 Angiotensin-receptor blockers (ARBs) can deplete collagen I 21:30 Overall survival in patients treated with ARB/ACE-I 22:26 Vascular normalization can enhance immunotherapy 24:06 Summary 27:01 Padmanee Sharma speaker profile 27:32 Investigating immune responses to immune checkpoint therapies 27:53 T cells can adapt to antigenic changes, have specificity and memory 29:02 Tumor infiltrating lymphocytes correlate with clinical benefit in cancer patients 30:04 How can we drive T cells into tumors? 33:20 Complete responder: melanoma 34:36 Complete responder with anti-PD-1: metastatic renal cell cancer 35:08 Clinical activity in melanoma patients receiving ipilimumab and nivolumab 37:20 Pre-surgical clinical trial with anti-CTLA4 in patients with localized urothelial carcinoma 38:23 Power of pre-surgical trials: in-depth immune monitoring in matched tumors and blood samples 38:37 IHC demonstrating infiltrating T cells in prostate tumor tissues after immunotherapy 39:48 Increased frequency of ICOS+ T cells in tumors from anti-CTLA-4 treated patients 41:27 Targeting ICOS in combination with anti-CTLA-4 improves tumor rejection 43:13 Novel immunotherapy targets 43:27 Conclusions 44:35 Questions and answers About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks #Antibody #CSTWebinar